FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036762572> ?p ?o ?g. }

• W3036762572 endingPage "e000222" @default.
• W3036762572 startingPage "e000222" @default.
• W3036762572 abstract "Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD) and recommended phase 2 dose of E7046. Methods This first-in-human study enrolled 30 patients with advanced tumors of cancer types associated with high levels of myeloid infiltrates. E7046 was administered orally once-daily in sequential escalating dose cohorts (125, 250, 500, and 750 mg) with ≥6 patients per cohort. Tumor assessments were performed every 6 weeks. Paired tumor biopsies and blood samples, before and on treatment, were collected for pharmacokinetic and pharmacodynamic characterization of the treatment. Results No dose-limiting toxicities were observed, and the MTD was not reached. E7046 had an elimination half-life (t 1/2 ) of 12 hours, and drug exposure increased dose-dependently from 125 to 500 mg. Target modulation by E7046 was supported by changes in genes downstream of EP4 with concurrent enhanced antitumoral immune responses. A best response of stable disease (per irRECIST) was reported in 23% of patients treated with E7046 (n=30) (125 mg: n=2; 250 mg: n=2; 750 mg: n=3). Over half (4/7) of the patients with stable disease had treatment duration of 18 weeks or more, and three patients (3/15; 20%) achieved metabolic responses. Conclusions In this first-in-human study, E7046 administered orally once daily demonstrated manageable tolerability, immunomodulatory effects, and a best response of stable disease (≥18 weeks) in several heavily pretreated patients with advanced malignancies. The 250 and 500 mg doses are proposed for further development in the combination setting. Trial registration number NCT02540291 ." @default.
• W3036762572 created "2020-06-25" @default.
• W3036762572 creator A5000133539 @default.
• W3036762572 creator A5005436649 @default.
• W3036762572 creator A5015881755 @default.
• W3036762572 creator A5026095888 @default.
• W3036762572 creator A5034115525 @default.
• W3036762572 creator A5034358405 @default.
• W3036762572 creator A5034376000 @default.
• W3036762572 creator A5038808458 @default.
• W3036762572 creator A5039878413 @default.
• W3036762572 creator A5045419282 @default.
• W3036762572 creator A5045462016 @default.
• W3036762572 creator A5048397234 @default.
• W3036762572 creator A5056255214 @default.
• W3036762572 creator A5058531053 @default.
• W3036762572 creator A5064852158 @default.
• W3036762572 creator A5065206480 @default.
• W3036762572 creator A5068275493 @default.
• W3036762572 creator A5070799369 @default.
• W3036762572 creator A5076426660 @default.
• W3036762572 creator A5083205599 @default.
• W3036762572 date "2020-06-01" @default.
• W3036762572 modified "2023-10-09" @default.
• W3036762572 title "First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE₂-receptor E-type 4 (EP4), in patients with advanced cancers" @default.
• W3036762572 cites W1589179725 @default.
• W3036762572 cites W1910012553 @default.
• W3036762572 cites W1981291019 @default.
• W3036762572 cites W1984257684 @default.
• W3036762572 cites W2031756196 @default.
• W3036762572 cites W2049873925 @default.
• W3036762572 cites W2058648826 @default.
• W3036762572 cites W2062265555 @default.
• W3036762572 cites W2066671159 @default.
• W3036762572 cites W2076743146 @default.
• W3036762572 cites W2101195992 @default.
• W3036762572 cites W2108549165 @default.
• W3036762572 cites W2116691163 @default.
• W3036762572 cites W2117348416 @default.
• W3036762572 cites W2117692326 @default.
• W3036762572 cites W2128149258 @default.
• W3036762572 cites W2128611559 @default.
• W3036762572 cites W2129018264 @default.
• W3036762572 cites W2173448806 @default.
• W3036762572 cites W2219429162 @default.
• W3036762572 cites W2528749195 @default.
• W3036762572 cites W2570766240 @default.
• W3036762572 cites W2582414407 @default.
• W3036762572 cites W2612431515 @default.
• W3036762572 cites W2727513755 @default.
• W3036762572 cites W2728594144 @default.
• W3036762572 cites W2737542013 @default.
• W3036762572 doi "https://doi.org/10.1136/jitc-2019-000222" @default.
• W3036762572 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7304851" @default.
• W3036762572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32554609" @default.
• W3036762572 hasPublicationYear "2020" @default.
• W3036762572 type Work @default.
• W3036762572 sameAs 3036762572 @default.
• W3036762572 citedByCount "26" @default.
• W3036762572 countsByYear W30367625722021 @default.
• W3036762572 countsByYear W30367625722022 @default.
• W3036762572 countsByYear W30367625722023 @default.
• W3036762572 crossrefType "journal-article" @default.
• W3036762572 hasAuthorship W3036762572A5000133539 @default.
• W3036762572 hasAuthorship W3036762572A5005436649 @default.
• W3036762572 hasAuthorship W3036762572A5015881755 @default.
• W3036762572 hasAuthorship W3036762572A5026095888 @default.
• W3036762572 hasAuthorship W3036762572A5034115525 @default.
• W3036762572 hasAuthorship W3036762572A5034358405 @default.
• W3036762572 hasAuthorship W3036762572A5034376000 @default.
• W3036762572 hasAuthorship W3036762572A5038808458 @default.
• W3036762572 hasAuthorship W3036762572A5039878413 @default.
• W3036762572 hasAuthorship W3036762572A5045419282 @default.
• W3036762572 hasAuthorship W3036762572A5045462016 @default.
• W3036762572 hasAuthorship W3036762572A5048397234 @default.
• W3036762572 hasAuthorship W3036762572A5056255214 @default.
• W3036762572 hasAuthorship W3036762572A5058531053 @default.
• W3036762572 hasAuthorship W3036762572A5064852158 @default.
• W3036762572 hasAuthorship W3036762572A5065206480 @default.
• W3036762572 hasAuthorship W3036762572A5068275493 @default.
• W3036762572 hasAuthorship W3036762572A5070799369 @default.
• W3036762572 hasAuthorship W3036762572A5076426660 @default.
• W3036762572 hasAuthorship W3036762572A5083205599 @default.
• W3036762572 hasBestOaLocation W30367625721 @default.
• W3036762572 hasConcept C111113717 @default.
• W3036762572 hasConcept C112705442 @default.
• W3036762572 hasConcept C126322002 @default.
• W3036762572 hasConcept C170493617 @default.
• W3036762572 hasConcept C197934379 @default.
• W3036762572 hasConcept C203014093 @default.
• W3036762572 hasConcept C2776885963 @default.
• W3036762572 hasConcept C2778375690 @default.
• W3036762572 hasConcept C71924100 @default.
• W3036762572 hasConcept C8891405 @default.
• W3036762572 hasConcept C98274493 @default.
• W3036762572 hasConceptScore W3036762572C111113717 @default.
• W3036762572 hasConceptScore W3036762572C112705442 @default.
• W3036762572 hasConceptScore W3036762572C126322002 @default.

• next